The hepoxilin stable analogue, PBT-3, inhibits primary, platelet-related hemostasis in whole blood measured in vitro with the PFA-100

Thrombosis Research

Volumn 112, Issue 4, 2003, Pages 245-248

  Reynaud, Denis ^a   Clark, Dewi ^a   Qiao, Na ^a   Rand, Margaret L ^a,b   Pace Asciak, Cecil R ^a,c  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b Depts of Lab Med and Pathology   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Closure time; PBT 3; PFA 100 ; Thromboxane antagonists; Whole blood

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; HEPOXILIN A; PINANE THROMBOXANE A2;

ARTICLE; AUTOANALYZER; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; HEMOSTASIS; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 1342345207     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.014     Document Type: Article

References (13)

1. Pace-Asciak C.R. Hepoxilins: a review of their cellular actions. Biochim. Biophys. Acta. 1215:1994;1-8.
2. Pace-Asciak C.R., Reynaud D., Demin P.M. Hepoxilins: a review on their enzymatic formation, metabolism and chemical synthesis. Lipids. 30:1995;1-8.
3. Pace-Asciak CR, Reynaud D, Demin P, Nigam S. The hepoxilins. A review. In: Nigam S, Pace-Asciak CR, editors. Lipoxygenases and their metabolites - biological functions. Advances in experimental medicine and biology, vol. 447. Kluwer Academic Publishing/Plenum; 1999 p. 123-132.
4. Demin P.M., Pace-Asciak C.R. Synthesis of racemic 11,12-cyclopropyl analogs of hepoxilins A3 and B3. Tetrahedron Lett. 34:1993;4305-4430.
5. Jankov R.P., Luo X., Demin P., Aslam R., Hannam V., Tanswell A.K.et al. Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse. J. Pharmacol. Exp. Ther. 301:2002;435-440.
6. Reynaud D., Hinek A., Pace-Asciak C.R. The hepoxilin analog PBT-3 inhibits heparin-activated platelet aggregation evoked by ADP. FEBS Lett. 515:2002;58-60.
7. Pace-Asciak C.R., Reynaud D., Demin P., Aslam R., Sun A. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J. Pharmacol. Exp. Ther. 301:2002;618-624.
8. Ogletree M.L., Harris D.N., Greenberg R., Haslanger M., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234:1985;435-441.
9. 3. Bioorg. Khim. 17:1991;1133-1140.
10. Kundu S., Heilmann E., Sio R., Garcia C., Davidson R., Ostgaart R. Description of an in vitro platelet function analyzer-PFA-100. Semin. Thromb. Hemost. 21:1995;106-112.
11. Kundu S., Heilmann E., Sio R., Garcia C., Davidson R., Ostgaart R. Characterization of an in-vitro platelet function analyzer PFA-100™ Clin. Appl. Thromb./Hemost. 2:1996;241-249.
12. Carcao M.D., Blanchette V.S., Dean J.A., He L., Kern M.A., Stain A.M.et al. The platelet function analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br. J. Haematol. 101:1998;70-73.
13. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J. Lab. Clin. Med. 138:2001;152-163.